RxDoctor Payments Data

Julie Papatheofanis, MD

Internal Medicine · la Jolla, CANPI 1467453381

Payments from drug & device makers

$862in general payments, 2019–2025

Across 31 payments — averaging $27.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$159
  • Pfizer$125
  • Johnson & Johnson$106
  • Novo Nordisk$97
  • AbbVie$91
  • GSK$69
  • plus $216 from 8 others

What the payments were for

  • Food & beverage$78291%
  • Education$809%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$862 in reported general payments places this provider in the 70th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$388,083
Medicare patients
883
Services billed
3,840

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban60$67,042
OzempicSemaglutide36$49,073
JardianceEmpagliflozin34$42,465
XareltoRivaroxaban27$28,185
MounjaroTirzepatide13$18,434
TrulicityDulaglutide15$16,593
MyrbetriqMirabegron11$13,436
PremproEstrogen,con/M-Progest Acet21$10,143
SynthroidLevothyroxine Sodium128$8,421
YuvafemEstradiol35$8,221
NamzaricMemantine Hcl/Donepezil Hcl14$7,465
Estradiol130$7,431
Levothyroxine Sodium626$7,335
TrintellixVortioxetine Hydrobromide16$7,269
PremarinEstrogens, Conjugated16$6,827

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Prempro, Premarin$125$84,01197 claims
Novo NordiskOzempic$97$49,07336 claims
Lilly USA, LLCMounjaro, Trulicity$29$35,02628 claims
Johnson & JohnsonXarelto$106$28,18527 claims
AbbVieSynthroid, Namzaric$91$15,886142 claims
Astellas Pharma US IncMyrbetriq$39$13,43611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 13,581 internal medicine providers in California.

Other internal medicine in la Jolla

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →